Komodo Grows Its MapEnhance Offering, Expanding Access to New Social Determinants of Health Insights Alongside Real-World Oncology Data and Rare Disease Genomics
13 Mayo 2024 - 7:00AM
Business Wire
As Komodo Adds More Data Products and Partners,
MapEnhance Provides Alternative to Data Marketplaces for
Unparalleled Context and Dimension into Patient Care and
Outcomes
Today, Komodo Health announced a series of updates to its
MapEnhanceTM offering, increasing the depth and volume of insights
into social determinants of health (SDOH). The company also
introduced two new specialty data partners, GeneDx and COTA
Healthcare. With this news, companies can tap into Komodo’s fully
integrated analytics solution to access the industry’s most
complete view of clinical encounters and gain a more holistic
understanding of the social and environmental factors that may
impact patient outcomes.
MapEnhance, available only through Komodo’s AI-powered platform,
features a library of specialty datasets from Komodo and its
partners — ranging from laboratory and genomics insights to
electronic health records, mortality, race and ethnicity, and more
— that can be linked with the Healthcare Map to advance in-depth
longitudinal research across every category of disease. As Komodo
broadens its SDOH intelligence to reach census-level visibility,
users can combine this information with any of the clinical
datasets within MapEnhance to more easily investigate how social,
economic, and environmental factors can influence a patient’s
health and outcomes beyond clinical interactions.
“In a landscape where healthcare costs are skyrocketing, the
demand for accurate, nuanced, and unbiased data has never been more
critical,” said Brad Kelley, General Manager of MapEnhance, Komodo
Health. “By adding insights into the social determinants of health
along with oncology and rare disease genomics data, we are
strengthening the ability of MapEnhance to power insights that can
lead to important commercial strategies and medical breakthroughs —
and we’re doing it with greater speed and accuracy than anything
else on the market today.”
MapEnhance features a network of specialty data partners,
including Invitae, PointClickCare, Trio Health — and now, GeneDx
and COTA Healthcare. The new partnerships will increase access to
GeneDx's extensive de-identified genetic rare disease dataset,
which includes data from more than 600,000 exomes and genomes, to
help inform drug pipelines and accelerate clinical trial
enrollment. Additionally, the combination of COTA’s deep clinical
cancer information and insights from other MapEnhance data products
is helping Life Sciences researchers across the enterprise discern
context and optimal moments for impactful decisions along the
cancer patient care journey.
“Integrating GeneDx's robust genetic dataset with Komodo's
expansive Healthcare Map marks a significant leap forward in
increasing access to genomic information to help advance precision
medicine,” said Melanie Duquette, Chief Growth Officer, GeneDx.
“Through our partnership, we can help companies unearth deeper
genetic insights to accelerate drug discovery, unlocking treatment
options for patients in need.”
“Our partnership with Komodo is an important opportunity to
provide a more complete view of cancer patients and outcomes as
their treatment journeys grow more varied and complex,” said Sandy
Leonard, Chief Commercial Officer, COTA. “Together, we are creating
comprehensive real-world data and evidence to accelerate the
development of more effective cancer treatments.”
In addition to its partner network, Komodo has expanded the
MapEnhance library to include a range of exclusive, Komodo-built
data assets. The new data enhancements — which include clinical
observations, laboratory results, self-identified race and
ethnicity, patient insurance status, and mortality — are highly
curated by Komodo’s leading data scientists and AI experts to help
deepen the visibility of the Healthcare Map and in turn, clinical
encounters and patient populations using a fully integrated
solution.
Researchers from top institutions and Life Sciences companies
leveraged MapEnhance and Komodo’s platform to power dozens of new
studies presented at ISPOR 2024, that shed light on important
disease trends spanning women’s health, oncology, mental health,
hypertension, neurology, and more. In an analysis that was
recognized among the top 5% of studies at ISPOR this year,
researchers linked data from the Healthcare Map with lab insights
from MapEnhance to examine the impact of the Clozapine Risk
Evaluation and Mitigation Strategy, an FDA-mandated safety
initiative, on the occurrence of neutropenia outcomes among
clozapine users since the program update in 2019.
All MapEnhance data products come de-identified and ready to
use, offering faster and timelier access to in-depth insights that
can help to reduce the global burden of disease. Komodo offers the
industry’s most rigorous process for de-duplicating, normalizing,
analyzing, and correcting the data that enters its Healthcare
Map.
About Komodo Health
Komodo Health is a technology platform company creating the new
standard for real-world data and analytics by pairing the
industry’s most complete view of patient encounters with enterprise
software and machine learning that connects the dots between
individual patient journeys and large-scale health outcomes. Across
Life Sciences, payers, providers, and developers, Komodo helps its
customers unearth patient-centric insights at scale — marrying
clinical data with advanced algorithms and AI-powered software
solutions to inform decision-making, close gaps in care, address
disease burden, and help enterprises create a more cost-effective,
value-driven healthcare system. For more information, visit
Komodohealth.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240513602333/en/
media@komodohealth.com